<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endogenous and synthetic cannabinoids exert antiproliferative and proapoptotic effects in various types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and in mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we evaluated the expression of cannabinoid receptors type 1 and type 2 (CB1 and CB2) in non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of B cell type (n = 62) </plain></SENT>
<SENT sid="2" pm="."><plain>A majority of the <z:hpo ids='HP_0002665'>lymphomas</z:hpo> expressed higher <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of CB1 and/or CB2 as compared to reactive lymphoid tissue </plain></SENT>
<SENT sid="3" pm="."><plain>With the exception of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, which uniformly overexpresses both CB1 and CB2, the levels of cannabinoid receptors within other <z:hpo ids='HP_0002665'>lymphoma</z:hpo> entities were highly variable, ranging from 0.1 to 224 times the expression in reactive lymph nodes </plain></SENT>
<SENT sid="4" pm="."><plain>Low levels of the splice variant CB1a, previously shown to have a different affinity for cannabinoids than CB1, were detected in 44% of the <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, while CB1b expression was not detected </plain></SENT>
<SENT sid="5" pm="."><plain>In functional studies using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), <z:hpo ids='HP_0005550'>chronic lymphatic leukemia</z:hpo> (CLL) and plasma cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> cell lines, the stable <z:chebi fb="0" ids="2700">anandamide</z:chebi> analog R(+)-methanandamide (R(+)-MA) induced cell <z:hpo ids='HP_0011420'>death</z:hpo> only in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and CLL cells, which overexpressed both cannabinoid receptors, but not in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo treatment with R(+)-MA caused a significant reduction of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size and mitotic index in mice xenografted with human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Together, our results suggest that therapies using cannabinoid receptor ligands will have efficiency in reducing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden in malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> overexpressing CB1 and CB2 </plain></SENT>
</text></document>